AU664375B2 - Novel composition of angiotensin-II receptor antagonists and calcium channel blockers - Google Patents

Novel composition of angiotensin-II receptor antagonists and calcium channel blockers Download PDF

Info

Publication number
AU664375B2
AU664375B2 AU20269/92A AU2026992A AU664375B2 AU 664375 B2 AU664375 B2 AU 664375B2 AU 20269/92 A AU20269/92 A AU 20269/92A AU 2026992 A AU2026992 A AU 2026992A AU 664375 B2 AU664375 B2 AU 664375B2
Authority
AU
Australia
Prior art keywords
biphenyl
methyl
propyl
acid
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU20269/92A
Other languages
English (en)
Other versions
AU2026992A (en
Inventor
Pancras Chor Bun Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Publication of AU2026992A publication Critical patent/AU2026992A/en
Application granted granted Critical
Publication of AU664375B2 publication Critical patent/AU664375B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU20269/92A 1991-05-15 1992-05-14 Novel composition of angiotensin-II receptor antagonists and calcium channel blockers Expired AU664375B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15
US700740 1991-05-15
PCT/US1992/003873 WO1992020342A1 (en) 1991-05-15 1992-05-14 Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers

Publications (2)

Publication Number Publication Date
AU2026992A AU2026992A (en) 1992-12-30
AU664375B2 true AU664375B2 (en) 1995-11-16

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20269/92A Expired AU664375B2 (en) 1991-05-15 1992-05-14 Novel composition of angiotensin-II receptor antagonists and calcium channel blockers

Country Status (11)

Country Link
EP (1) EP0584250A1 (enExample)
JP (1) JP2930252B2 (enExample)
AU (1) AU664375B2 (enExample)
CA (1) CA2103276A1 (enExample)
CZ (1) CZ281570B6 (enExample)
IE (1) IE921534A1 (enExample)
IL (1) IL101858A (enExample)
MX (1) MX9202243A (enExample)
NZ (1) NZ242724A (enExample)
WO (1) WO1992020342A1 (enExample)
ZA (1) ZA923557B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
ES2193233T3 (es) 1995-03-16 2003-11-01 Pfizer Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
ES2552639T3 (es) 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
JP2004514703A (ja) * 2000-12-01 2004-05-20 ノバルティス　アクチエンゲゼルシャフト 有機化合物の組合せ剤
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
MXPA05008142A (es) * 2003-01-31 2005-09-30 Sankyo Co Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension.
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20240805T1 (hr) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pročišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i uporabe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
DK0565634T3 (da) * 1990-12-14 1999-09-27 Smithkline Beecham Corp Angiotensin-II-receptorblokkersammensætninger

Also Published As

Publication number Publication date
JPH06508128A (ja) 1994-09-14
IL101858A (en) 1996-08-04
WO1992020342A1 (en) 1992-11-26
AU2026992A (en) 1992-12-30
JP2930252B2 (ja) 1999-08-03
CA2103276A1 (en) 1992-11-16
EP0584250A1 (en) 1994-03-02
EP0584250A4 (enExample) 1994-03-30
CZ235193A3 (en) 1994-03-16
CZ281570B6 (cs) 1996-11-13
ZA923557B (en) 1993-11-15
IL101858A0 (en) 1992-12-30
IE921534A1 (en) 1992-11-18
MX9202243A (es) 1992-11-01
NZ242724A (en) 1994-09-27

Similar Documents

Publication Publication Date Title
AU664375B2 (en) Novel composition of angiotensin-II receptor antagonists and calcium channel blockers
US5492904A (en) Composition of angiotensin-II receptor antagonists and calcium channel blockers
US4873076A (en) Method of safely providing anesthesia or conscious sedation
EP1306088A1 (en) Combination of a benzimidazole having angiotensin-II antagonistic activity with a diuretic
JPH11228410A (ja) イミダゾールアンジオテンシン−ｉｉ受容体拮抗薬からなる慢性腎不全治療剤
HU219404B (hu) Eljárás kardiális és vaszkuláris hipertrófia és/vagy hiperplazia kezelésére alkalmas angiotenzin-II-receptor blokkoló hatású vegyületet tartalmazó gyógyszerkészítmények előállítására
GB2270074A (en) Angiotensin II antagonist
US20080188497A1 (en) Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions
US5264447A (en) Angiotensin II antagonist
JP3057471B2 (ja) アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5639773A (en) Ocular hypotensive agent
EP0398326A2 (en) Serotonin antagonist
EP0368972B1 (en) Method of safely providing anesthesia or conscious sedation
EP0612523B1 (en) Vascular hypertrophy suppressor
KR100222627B1 (ko) 앙기오텐신-ii 수용체 길항제 및 칼슘 채널 차단제의 신규한 조성물
JPH0867674A (ja) 眼圧降下剤
WO1995015325A1 (en) Imidazolyl-alkenoic acids
WO2006028007A1 (ja) 糸球体疾患治療剤
JPWO2002092096A1 (ja) 抗腫瘍剤
HK1012209A1 (en) Angiotensin ii receptor blocking compositions
JP3639982B2 (ja) カルボキシメチリデンシクロヘプトイミダゾ−ル誘導体の易吸収性経口用医薬組成物
GB2227664A (en) Treating hypertension using a thromboxane A2 receptor antagonist
HK1089941A (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention